文献速递血栓与止血造血干细胞移植与细胞治疗

乳腺癌患者接受CDK抑制剂治疗中的静脉血栓栓塞症

Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors.
PubMed 文献 · J Thromb Haemost · 2019-09-18

该回顾性队列研究纳入2015至2017年接受FDA批准CDK抑制剂(CDKI)治疗的424例转移性乳腺癌患者,评估静脉血栓栓塞(VTE)发生率及与结局的关联。结果显示1年VTE累积发生率为6.3%,高于随机试验报告的0.6%-5%;

要点

  • 临床实践中CDKI治疗mBC的VTE率比注册试验高2-5倍。
  • VTE与PFS和OS恶化呈趋势但未达统计学显著。
  • 需警惕CDKI治疗患者的VTE风险,尤其深静脉血栓和内脏静脉血栓。

核心结论

  • 临床实践中CDKI治疗mBC的VTE发生率(1年6.3%)比注册试验报告的0.6%-5%高2-5倍,且可能与更差结局相关。

研究设计与样本

  • 通过电子病历审查识别VTE(包括DVT、PE和VVT),采用Cox比例风险回归评估VTE与OS和PFS的关联。

主要发现

  • Palbociclib是最常用CDKI(390例,91.8%)。
  • 38例患者在CDKI治疗期间发生VTE,1年累积发生率为6.3%,其中DVT占52.6%、PE占18.5%、VVT占15.8%。
  • VTE发生的中位时间为314天。

临床怎么用

  • 临床实践中应提高对CDKI治疗mBC患者VTE风险的警惕,VTE发生率可能高于试验报告。
  • 对接受CDKI治疗的患者应考虑VTE监测和风险评估,尤其关注DVT、PE和VVT。

局限性

  • 回顾性研究设计,VTE识别依赖于电子病历审查,可能存在漏诊或误分类。
  • VTE与生存结局的关联未达统计学显著,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism (VTE) complicates several anticancer regimens including chemotherapy and antiangiogenic agents. Cyclin-dependent kinase inhibitors (CDKIs) are a new approach for hormone receptor-positive metastatic breast cancer (mBC). Reported VTE rates in randomized trials range from 0.6% to 5%, but these may underestimate actual rates observed in clinical practice. OBJECTIVES: Evaluate VTE rate and its association with outcomes in CDKIs patients. PATIENTS/METHODS: We conducted a retrospective cohort study of consecutive mBC patients who received any of three Food and Drug Administration (FDA)-approved CDKIs (palbociclib, ribociclib, abemaciclib) from January 2015 through December 2017. Venous thromboembolism including deep venous thrombosis (DVT), pulmonary embolism (PE), and visceral vein thrombosis (VVT) were identified by electronic medical record review. Overall survival (OS) and progression-free survival (PFS) were estimated and evaluated for association with VTE using Cox proportional hazard regression. RESULTS: We included 424 patients, with a median age at diagnosis of 55 years. Palbociclib was the most commonly used CDKI (n = 390, 91.8%). Venous thromboembolism during CDKIs occurred in 38 patients, 6.3% at year 1, including DVT in 52.6%, PE in 18.5%, and VVT in 15.8%. Median time to VTE was 314 days. Venous thromboembolism was associated with a trend to worse PFS and OS in multivariate analysis [PFS hazard ratio (HR) 1.40, 95% confidence interval (CI) 0.83-2.38, P = .21], OS (HR 1.70, 95% CI 0.95-2.98, P = .076). CONCLUSIONS: Venous thromboembolism rates with CDKI treatment in mBC in clinical practice are 2-fold to 5-fold greater than reported in registration trials and may be associated with worse outcomes.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Gervaso L, Montero AJ, Jia X, et al. Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors. J Thromb Haemost. 2019. PMID: 31479568. doi:10.1111/jth.14630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。